Fair value · biote Corp. (BTMD) · updated 2026-09-13 · from 10-K FY2025
biote trades at $1.33. That price implies a P/E of 13.3×, 10.0% yearly EPS growth for a decade, 3.2× EV/EBITDA and a 16.7% free-cash-flow yield.
Cboe · delayed 15 min · as of 03:40 ET
Are those assumptions reasonable? Use BTMD’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- P/E
- 13.3×
- EPS growth
- 10.0%
- EV/EBITDA
- 3.2×
- FCF yield
- 16.7%
price ÷ trailing EPS
per year for 10 years, discounted at 10%
(market cap + net debt) ÷ EBITDA
free cash flow ÷ enterprise value (6.0× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 03:40 ET.
The filing behind these numbers
biote Corp.- Revenue
- $192.2M
- Diluted EPS
- $0.74
- Free cash flow
- $30.2M
- operating cash flow − capital expenditure
- Diluted shares
- 36.7M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-13 · accession 0001193125-26-106099
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-07).
Open this filing on sec.govNeed BTMD data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.